Program
turmetabart adizutecan
In AbbVie’s pipeline, SEZ6
. Its studies are mostly in Small Cell Lung Carcinoma · Neoplasms, led by AbbVie.
Furthest: phase 3, since Jan 22, 20265 company-led studies, 5 open or runningNext primary completion: Nov 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 55 open or running | phase 3since Jan 22, 2026 | Oct 28, 2022 | Nov 2027phase 1 · NCT05599984 |
- Named in AbbVie’s own pipeline as
ABBV-706
, phase 3, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 28, 2022First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT05599984 · 288 enrolled · United States, Australia, China and more
- Aug 28, 2025Phase 2 study in Small Cell Lung CarcinomaNCT07155174 · 180 planned · United States, Belgium, China and more
- Jan 22, 2026Phase 3 study in Small Cell Lung CarcinomaPhase 3 reachedNCT07365241 · 531 planned · United States, Austria, Belgium and more
- Oct 20, 20262 phase 2 studies in NeoplasmsNCT07895056, NCT07895043
Ahead
- Nov 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT05599984
- Apr 2029Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07155174
- Sep 2030Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT07365241
- Aug 2031Primary completion: phase 2 study in NeoplasmsNCT07895056
TargetBeta
“SEZ6”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of turmetabart, a monoclonal antibody directed against seizure protein 6 homolog (SEZ6), ”NCIt, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07895056Neoplasms | 2 | Not yet recruiting | Aug 2031 | 80 |
| NCT07895043Neoplasms | 2 | Not yet recruiting | Dec 2031 | 80 |
| NCT07365241Small Cell Lung Carcinoma · United States, Austria, Belgium and more | 3 | Recruiting | Sep 2030 | 531 |
| NCT07155174Small Cell Lung Carcinoma · United States, Belgium, China and more | 2 | Recruiting | Apr 2029 | 180 |
| NCT05599984Small Cell Lung Carcinoma · United States, Australia, China and more | 1 | Active, not recruiting | Nov 2027 | 288 |
How it is read
Names in the registry
- “ABBV-706”, 5 entries
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 3 studies
- Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.